Oral t cell therapy

Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a rare cutaneous neoplasm of mature cytotoxic T-cells. Currently there are no standardized therapies for SPTL; however good responses have been seen with chemotherapy regimens generally employed for B-cell lymphomas. Cyclosporine, an immunosuppressant, has shown good responses in relapsed/refractory SPTL; however its use in first line setting is not well established. We, herein, describe a 22-year-old girl with disseminated SPTL who attained complete clinical remission with single agent oral cyclosporine used as a first line therapy.

  • Watch Gardner explain more about reprogramming the body’s immune system to fight cancer.
  • Find more details about the PLAT clinical trials and other cancer clinical trials at Seattle Children's on . Read our guide about searching for trials on (PDF).
  • Learn how T-cell therapy put 3-year-old Greta in remission .
  • Meet Milton Wright III , a young adult who took part in the study after learning he had leukemia for the third time.
  • Learn about the Ben Towne Center for Childhood Cancer Research and the Jensen Lab .
  • Read more about ALL and the immune system .

Oral t cell therapy

oral t cell therapy


oral t cell therapyoral t cell therapyoral t cell therapyoral t cell therapyoral t cell therapy